Methotrexate dose

With the exception of alopecia, photosensitivity, and "burning of skin lesions" , the adverse reaction rates in these reports were very similar to those in the rheumatoid arthritis studies. Dosages ranged up to 25 mg per week and treatment was administered for up to four years. There are two literature reports describing large series of psoriasis patients treated with Methotrexate. There are no recent placebo-controlled trials in patients with psoriasis. Two other controlled trials of patients with Rheumatoid Arthritis on 7.5 mg to 15 mg/wk oral doses showed an incidence of interstitial pneumonitis of 1%. Hepatic histology was not examined in these short-term studies. Virtually all of these patients were on concomitant nonsteroidal anti-inflammatory drugs and some were also taking low dosages of corticosteroids. The approximate incidences of Methotrexate attributed adverse reactions in 12 to 18 week double-blind studies of patients with rheumatoid arthritis treated with low-dose oral pulse Methotrexate are listed below. Anaphylactoid reactions have been reported. Other rarer reactions related to or attributed to the use of Methotrexate such as nodulosis, vasculitis, arthralgia/myalgia, loss of libido/impotence, diabetes, osteoporosis, sudden death, reversible lymphomas, tumor lysis syndrome, soft tissue necrosis and osteonecrosis.